Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERC-002 · 1 trial · 3 indications
Respiratory failure defined based on resource utilization requiring at least one of the following: * Endotracheal intubation and mechanical ventilation * Oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates \>20L/min with fraction of delivered oxygen ≥0.5) * Noninvasive positive pressure ventilation, * Extracorporeal membrane oxygenation
| Arm | Type | Description |
|---|---|---|
| CERC-002 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CERC-002 | DRUG | Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg. |
| Placebo | DRUG | Administered once subcutaneously |
Inclusion Criteria: 1. Subject/legally authorized representative (LAR) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study. 2. Subject is ≥18 years of age at the time of informed consent and assent (as applicable). 3. Subject is male o...
CERC-002 is an investigational small molecule being studied for the treatment of COVID-19 pneumonia and acute lung injury. It was evaluated in a Phase 2 clinical trial in adults with these conditions. The drug is not approved and remains in clinical development.
CERC-002 is being developed by Avalo Therapeutics, Inc., a biopharmaceutical company. The company's stock trades under the ticker symbol AVTX. Avalo Therapeutics is responsible for the clinical development of this investigational drug.
CERC-002 is in Phase 2 clinical development. It has completed a Phase 2 trial for COVID-19 pneumonia and acute lung injury. The drug is investigational and has not been approved by regulatory authorities.
CERC-002 has been studied in one clinical trial, identified as NCT04412057. This was a Phase 2, randomized, double-blind, placebo-controlled trial in adults with COVID-19 pneumonia and acute lung injury. The trial enrolled 88 participants and has been completed.
CERC-002 is the sole name provided for this investigational drug. No alternative names have been mentioned in the available information. It is being developed by Avalo Therapeutics for COVID-19 pneumonia and acute lung injury.